Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
Malavika Deodhar(Research & Development Institute), Véronique Michaud(Research & Development Institute), Lucy I. Darakjian(Research & Development Institute), Jacques Turgeon(Unknown), Meghan J. Arwood(Research & Development Institute), Pamela Dow(Research & Development Institute), Sweilem B. Al Rihani(Moderna Therapeutics (United States))
Cited by 237
Related Papers
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
|Annals of Pharmacotherapy|2013|186
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
|PubMed|1999|177
Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders
|Circulation|2000|164
Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval
|Circulation|1998|161
Effect of a low-glycaemic index–low-fat–high protein diet on the atherogenic metabolic risk profile of abdominally obese men
|British Journal Of Nutrition|2001|140